Acquired by Novo Nordisk in Oct 2022
FMTX - Forma Therapeutics Holdings, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Watertown,
United States
Type: Equity
FMTX price evolution
FMTX
| (in millions $) | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 | 30 Sep 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $75.14 | $74.42 | $77.42 | $87.25 |
| Short term investments | $320.77 | $346.94 | $386.81 | $425.43 |
| Net receivables | $15.37 | $13.75 | $13.07 | $14.07 |
| Inventory | ||||
| Total current assets | $426.45 | $446.52 | $486.4 | $534.89 |
| Long term investments | $19.98 | $26.05 | $19.09 | |
| Property, plant & equipment | $35.89 | $35.17 | $36 | $35.31 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $48.72 | $67.97 | $74.66 | $67.34 |
| Total investments | $320.77 | $366.93 | $412.85 | $444.52 |
| Total assets | $475.17 | $514.5 | $561.06 | $602.23 |
| Current liabilities | ||||
| Accounts payable | $3.04 | $2.04 | $4.14 | $4.59 |
| Deferred revenue | ||||
| Short long term debt | $5.33 | $5.11 | $5.13 | $4.54 |
| Total current liabilities | $33.46 | $26.34 | $35.09 | $32.63 |
| Long term debt | $27.21 | $26.97 | $27.62 | $26.76 |
| Total noncurrent liabilities | $27.21 | $26.97 | $27.62 | $26.76 |
| Total debt | $32.55 | $32.08 | $32.74 | $31.3 |
| Total liabilities | $60.68 | $53.3 | $62.7 | $59.39 |
| Shareholders' equity | ||||
| Retained earnings | -$327.11 | -$274.53 | -$230.37 | -$180.25 |
| Other shareholder equity | ||||
| Total shareholder equity | $414.49 | $461.19 | $498.36 | $542.83 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $77.42 | $282.69 | $173.18 | $83.45 |
| Short term investments | $386.81 | $350.37 | $68.85 | |
| Net receivables | $13.07 | $15.27 | $0.23 | $97.94 |
| Inventory | ||||
| Total current assets | $486.4 | $654.45 | $177.31 | $255.38 |
| Long term investments | $26.05 | $12.53 | ||
| Property, plant & equipment | $36 | $1.52 | $5.1 | $7.24 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $74.66 | $26.52 | $5.72 | $7.86 |
| Total investments | $412.85 | $362.9 | ||
| Total assets | $561.06 | $680.97 | $183.03 | $263.24 |
| Current liabilities | ||||
| Accounts payable | $4.14 | $4.29 | $3.52 | $6.3 |
| Deferred revenue | $1.24 | $202.98 | ||
| Short long term debt | $5.13 | |||
| Total current liabilities | $35.09 | $31.7 | $24.87 | $233.71 |
| Long term debt | $27.62 | |||
| Total noncurrent liabilities | $27.62 | $1.03 | $1.79 | $78.4 |
| Total debt | $32.74 | |||
| Total liabilities | $62.7 | $32.73 | $26.66 | $245.66 |
| Shareholders' equity | ||||
| Retained earnings | -$230.37 | -$57.41 | $16.74 | -$54.65 |
| Other shareholder equity | $0.39 | $5.55 | ||
| Total shareholder equity | $498.36 | $648.24 | $18.25 | $17.58 |
| (in millions $) | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 | 30 Sep 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $39.06 | $31.27 | $37.05 | $30.68 |
| Selling, general & administrative | $13.94 | $13.14 | $13.24 | $12.75 |
| Total operating expenses | $53 | $44.41 | $50.28 | $43.43 |
| Operating income | -$53 | -$44.41 | -$50.28 | -$43.43 |
| Income from continuing operations | ||||
| EBIT | -$52.59 | -$44.16 | -$50.09 | -$43.29 |
| Income tax expense | -$0.01 | $0 | $0.03 | $0.01 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$52.58 | -$44.16 | -$50.13 | -$43.29 |
| Income (for common shares) | -$52.58 | -$44.16 | -$50.13 | -$43.29 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 30 Jan 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $100.56 | $164.09 | ||
| Cost of revenue | ||||
| Gross Profit | $100.56 | $164.09 | ||
| Operating activities | ||||
| Research & development | $125.66 | $93.37 | $111.31 | |
| Selling, general & administrative | $48.33 | $30.78 | $24.4 | |
| Total operating expenses | $173.99 | $124.21 | $141.01 | $154.4 |
| Operating income | -$173.99 | -$124.21 | -$40.45 | $9.69 |
| Income from continuing operations | ||||
| EBIT | -$172.81 | -$100.13 | -$36.64 | |
| Income tax expense | $0.15 | -$29.72 | -$1.85 | $8.57 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$172.96 | -$70.41 | -$34.79 | $5.29 |
| Income (for common shares) | -$172.96 | -$74.15 | -$52.75 | |
| (in millions $) | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 | 30 Sep 2021 |
|---|---|---|---|---|
| Net income | -$52.58 | -$44.16 | -$50.13 | -$43.29 |
| Operating activities | ||||
| Depreciation | $1.01 | $0.9 | $1.11 | $0.48 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $5.79 | $6.25 | $5.59 | $6.7 |
| Total cash flows from operations | -$44.76 | -$49.3 | -$41.2 | -$34.81 |
| Investing activities | ||||
| Capital expenditures | -$0.8 | -$0.26 | -$0.46 | -$3.54 |
| Investments | $46.32 | $45.93 | $31.45 | $75.14 |
| Total cash flows from investing | $45.52 | $45.66 | $30.99 | $71.6 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.09 | $0.74 | $0.06 | $0.03 |
| Net borrowings | ||||
| Total cash flows from financing | -$0.04 | $0.66 | $0.03 | -$0.41 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $0.72 | -$2.97 | -$10.18 | $36.38 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Net income | -$172.96 | -$70.41 | -$34.79 | $5.29 |
| Operating activities | ||||
| Depreciation | $2.59 | $1.28 | $2.67 | $3.53 |
| Business acquisitions & disposals | $17.84 | |||
| Stock-based compensation | $22.56 | $6.96 | $2.5 | |
| Total cash flows from operations | -$149.79 | -$95.42 | -$34.49 | -$132.83 |
| Investing activities | ||||
| Capital expenditures | -$4.18 | -$0.2 | -$0.53 | -$3.39 |
| Investments | -$51.2 | -$363.46 | $69.95 | |
| Total cash flows from investing | -$55.38 | -$345.82 | $69.42 | $99.09 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.51 | $552.86 | $0.01 | |
| Net borrowings | ||||
| Total cash flows from financing | -$0.46 | $552.6 | $54.8 | |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$205.62 | $111.36 | $89.73 | -$33.74 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 47.83M |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$186.63M |
| EBIT | -$190.13M |
| Net Income | -$190.16M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | 8.67 |
| Cash/Share | 1.57 |
| EPS | -$3.98 |
|---|---|
| ROA | -35.33% |
| ROE | -39.68% |
| Debt/Equity | 0.13 |
|---|---|
| Net debt/EBITDA | 0.08 |
| Current ratio | 12.74 |
| Quick ratio | 12.74 |